Prostate Cancer
9 drugs29,902 FAERS reportsMedDRA PT
GET
/api/v1/reaction/prostate-cancerReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
DefinitionNLM MeSH D011471
Tumors or cancer of the PROSTATE.
Source: U.S. National Library of Medicine — MeSH (Prostatic Neoplasms)
Drugs reporting Prostate Cancer (9)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Ranitidine26,44611%
- 2Flutamide707.1%
- 3Radium2193.1%
- 4Cabazitaxel1063.1%
- 5Darolutamide1262.5%
- 6Leuprolide1,8152.3%
- 7Abiraterone8822.2%
- 8Tetraxetan1191.0%
- 9Vipivotide Tetraxetan1191.0%
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
- Prostatic Specific Antigen Increased8 shared · 0.47
- Hormone-refractory Prostate Cancer4 shared · 0.44
- Prostate Cancer Metastatic4 shared · 0.40
- Metastases To Bone6 shared · 0.30
- Sars-cov-2 Test Positive2 shared · 0.18
- Laboratory Test Abnormal2 shared · 0.12
- Ill-defined Disorder2 shared · 0.08
- Hot Flush3 shared · 0.06
- Dry Mouth2 shared · 0.03
- General Physical Health Deterioration3 shared · 0.03
Literature
Recent PubMed references pinned to Prostatic Neoplasms as a MeSH major topic. About the reaction term itself — not about any specific drug.
- A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer.The Journal of experimental medicine · 2026 · Nunes de Almeida F, Vasciaveo A, Giacobbe A, et al.PMID 42207152DOI 10.1084/jem.20241484
- Determination of HU override for gold fiducial markers in proton therapy.Journal of applied clinical medical physics · 2026 · Zhang X, Andriotty M, Yue NJ, et al.PMID 42206595DOI 10.1002/acm2.70643
- Deep survival learning for prognosis prediction in non-metastatic castration-resistant prostate cancer.Health informatics journal · 2026 · Li C, Bohman J, Patil V, et al.PMID 42206427DOI 10.1177/14604582261456059
- Artificial Intelligence-Based Objective Evaluation of Nerve-Sparing Status Combined With Preserved Urethral Length Predicts Urinary Continence Recovery After Robot-Assisted Radical Prostatectomy.International journal of urology : official journal of the Japanese Urological Association · 2026 · Ando S, Del Aguila Moraga DA, Hoshina H, et al.PMID 42205081DOI 10.1111/iju.70514
- Retrospective analysis of adaptation frequencies and factors in offline in offline adaptive proton therapy.Journal of applied clinical medical physics · 2026 · Pak F, Zhang H, Hao Y, et al.PMID 42204770DOI 10.1002/acm2.70604
- Strategies for enhancing delivery efficiency on MR-Linac: A dosimetric study and historical plan review.Journal of applied clinical medical physics · 2026 · Zhang Y, Tang S, Kabat C, et al.PMID 42204767DOI 10.1002/acm2.70638
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.